The Candida albicans heat shock protein 90 kDa (hsp90-CA) is an important target for protective antibodies in disseminated candidiasis of experimental mice and humans. Hsp90-CA is present in the cell wall of Candida pseudohyphae or hyphae--typical pathogenic morphotypes in both mucosal and systemic Candida infections. However, the potential protective effects of hsp90-CA-specific antibodies in vaginal candidiasis has not yet been reported. In the present study we used various vaccine formulations (recombinant hsp90-CA protein and hsp90-CA-encoding DNA vaccine) and routes of administration (intradermal, intranasal, and intravenous) to induce both hsp90-CA-specific systemic and vaginal mucosa immune responses in experimental BALB/c mice. The results showed that intradermal recombinant hsp90-CA protein priming, followed by intranasal or intradermal recombinant hsp90-CA protein boosting induced significant increases in both serum and vaginal hsp90-CA-specific IgG and IgA antibodies compared to the control group, as well as enhanced hsp90-CA-specific splenocyte responses in vitro. In the intradermally boosted group, subsequent experimental vaginal Candida infection induced additional increases in the hsp90-CA specific IgG isotype, suggesting that Candida has the ability to induce a local hsp90-specific antibody (IgG) response during vulvovaginal candidiasis. Further work is required to elucidate the importance of immunity to highly conserved antigens during infection of the human female reproductive tract where a balance between immunity to and tolerance for commonly antigens such as hsp90 is necessary for the maintenance of fertility.

Department of Immunology Palacky University in Olomouc Olomouc Czech Republic

000      

03958naa 2200589 a 4500

001      

bmc11003905

003      

CZ-PrNML

005      

20121126093026.0

008      

110302s2008 xxk e eng||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxk

100    1_

$a Raška, Milan, $d 1967- $7 xx0060585

245    10

$a Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis / $c M. Raska, J. Belakova, M. Horynova, M. Krupka, J. Novotny, M. Sebestova, E. Weigl

314    __

$a Department of Immunology, Palacky University in Olomouc, Olomouc, Czech Republic. raskamil@uab.edu

520    9_

$a The Candida albicans heat shock protein 90 kDa (hsp90-CA) is an important target for protective antibodies in disseminated candidiasis of experimental mice and humans. Hsp90-CA is present in the cell wall of Candida pseudohyphae or hyphae--typical pathogenic morphotypes in both mucosal and systemic Candida infections. However, the potential protective effects of hsp90-CA-specific antibodies in vaginal candidiasis has not yet been reported. In the present study we used various vaccine formulations (recombinant hsp90-CA protein and hsp90-CA-encoding DNA vaccine) and routes of administration (intradermal, intranasal, and intravenous) to induce both hsp90-CA-specific systemic and vaginal mucosa immune responses in experimental BALB/c mice. The results showed that intradermal recombinant hsp90-CA protein priming, followed by intranasal or intradermal recombinant hsp90-CA protein boosting induced significant increases in both serum and vaginal hsp90-CA-specific IgG and IgA antibodies compared to the control group, as well as enhanced hsp90-CA-specific splenocyte responses in vitro. In the intradermally boosted group, subsequent experimental vaginal Candida infection induced additional increases in the hsp90-CA specific IgG isotype, suggesting that Candida has the ability to induce a local hsp90-specific antibody (IgG) response during vulvovaginal candidiasis. Further work is required to elucidate the importance of immunity to highly conserved antigens during infection of the human female reproductive tract where a balance between immunity to and tolerance for commonly antigens such as hsp90 is necessary for the maintenance of fertility.

650    _2

$a aplikace intranazální $7 D000281

650    _2

$a zvířata $7 D000818

650    _2

$a protilátky fungální $x analýza $x krev $7 D000908

650    _2

$a tvorba protilátek $7 D000917

650    _2

$a Candida albicans $x imunologie $7 D002176

650    _2

$a kandidóza vulvovaginální $x imunologie $7 D002181

650    _2

$a proliferace buněk $7 D049109

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a fungální proteiny $x imunologie $7 D005656

650    _2

$a fungální vakcíny $x aplikace a dávkování $x imunologie $7 D005657

650    _2

$a proteiny tepelného šoku HSP90 $x imunologie $7 D018841

650    _2

$a sekundární imunizace $7 D007117

650    _2

$a injekce intradermální $7 D007271

650    _2

$a injekce intravenózní $7 D007275

650    _2

$a lymfocyty $x imunologie $7 D008214

650    _2

$a myši $7 D051379

650    _2

$a myši inbrední BALB C $7 D008807

650    _2

$a slezina $x imunologie $7 D013154

650    _2

$a DNA vakcíny $x aplikace a dávkování $x imunologie $7 D019444

650    _2

$a syntetické vakcíny $x aplikace a dávkování $x imunologie $7 D014614

650    _2

$a vagina $x imunologie $x mikrobiologie $7 D014621

650    _2

$a financování organizované $7 D005381

700    1_

$a Běláková, Jana. $7 _AN054676

700    1_

$a Stuchlová Horynová, Milada. $7 xx0193186

700    1_

$a Křupka, Michal $7 xx0106791

700    1_

$a Novotný, J. $7 _AN052845

700    1_

$a Šebestová, Martina. $7 _AN060155

700    1_

$a Weigl, Evžen, $d 1948- $7 xx0060584

773    0_

$t Medical Mycology $w MED00005131 $g Roč. 46, č. 5 (2008), s. 411-420 $x 1369-3786

910    __

$a ABA008 $b x $y 6

990    __

$a 20110413090503 $b ABA008

991    __

$a 20121126093052 $b ABA008

999    __

$a ok $b bmc $g 831246 $s 695929

BAS    __

$a 3

BMC    __

$a 2008 $b 46 $c 5 $d 411-420 $i 1369-3786 $m Medical mycology $n Med Mycol $x MED00005131

LZP    __

$a 2011-3B/irme